For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $33.61 in the prior trading day, Stoke Therapeutics Inc (NASDAQ: STOK) closed at $32.86, down -2.23%. In other words, the price has decreased by -$2.23 from its previous closing price. On the day, 0.62 million shares were traded. STOK stock price reached its highest trading level at $34.05 during the session, while it also had its lowest trading level at $32.43.
Ratios:
Our goal is to gain a better understanding of STOK by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.84. For the most recent quarter (mrq), Quick Ratio is recorded 6.53 and its Current Ratio is at 6.53. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Jefferies on July 18, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On December 20, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $24.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 08 ’25 when Allan Jonathan sold 3,978 shares for $32.28 per share. The transaction valued at 128,411 led to the insider holds 11,831 shares of the business.
Kaye Edward M. MD sold 13,430 shares of STOK for $433,385 on Dec 08 ’25. The Director now owns 49,124 shares after completing the transaction at $32.27 per share. On Dec 08 ’25, another insider, EDWARD M KAYE, who serves as the Director of the company, bought 13,430 shares for $30.87 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, STOK now has a Market Capitalization of 1876869632 and an Enterprise Value of 1633341568. As of this moment, Stoke’s Price-to-Earnings (P/E) ratio for their current fiscal year is 49.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.13 while its Price-to-Book (P/B) ratio in mrq is 5.88. Its current Enterprise Value per Revenue stands at 7.943 whereas that against EBITDA is 56.154.
Stock Price History:
The Beta on a monthly basis for STOK is 1.09, which has changed by 1.9743364 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, STOK has reached a high of $38.69, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 9.04%, while the 200-Day Moving Average is calculated to be 89.22%.
Shares Statistics:
The stock has traded on average 1.20M shares per day over the past 3-months and 989080 shares per day over the last 10 days, according to various share statistics. A total of 55.12M shares are outstanding, with a floating share count of 46.32M. Insiders hold about 18.91% of the company’s shares, while institutions hold 104.10% stake in the company. Shares short for STOK as of 1764288000 were 10558093 with a Short Ratio of 8.81, compared to 1761868800 on 10666109. Therefore, it implies a Short% of Shares Outstanding of 10558093 and a Short% of Float of 22.16.
Earnings Estimates
The dynamic stock of Stoke Therapeutics Inc (STOK) is currently attracting attention from 8.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.69 and low estimates of -$0.83.
Analysts are recommending an EPS of between $0.26 and -$0.32 for the fiscal current year, implying an average EPS of $0.05. EPS for the following year is -$3.08, with 8.0 analysts recommending between -$2.3 and -$3.65.
Revenue Estimates
9 analysts predict $5.09M in revenue for. The current quarter. It ranges from a high estimate of $7M to a low estimate of $3M. As of. The current estimate, Stoke Therapeutics Inc’s year-ago sales were $22.61M
A total of 9 analysts have provided revenue estimates for STOK’s current fiscal year. The highest revenue estimate was $199.7M, while the lowest revenue estimate was $186.02M, resulting in an average revenue estimate of $189.25M. In the same quarter a year ago, actual revenue was $36.55M
